176 related articles for article (PubMed ID: 33783343)
41. Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model.
Ara R; Pandor A; Tumur I; Paisley S; Duenas A; Williams R; Rees A; Wilkinson A; Durrington P; Chilcott J
Am J Cardiovasc Drugs; 2008; 8(6):419-27. PubMed ID: 19159125
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
Farnier M; Jones P; Severance R; Averna M; Steinhagen-Thiessen E; Colhoun HM; Du Y; Hanotin C; Donahue S
Atherosclerosis; 2016 Jan; 244():138-46. PubMed ID: 26638010
[TBL] [Abstract][Full Text] [Related]
43. LDL cholesterol goals in high-risk patients: how low do we go and how do we get there?
Besseling J; van Capelleveen J; Kastelein JJ; Hovingh GK
Drugs; 2013 Mar; 73(4):293-301. PubMed ID: 23494186
[TBL] [Abstract][Full Text] [Related]
44. Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression.
Masson W; Lobo M; Siniawski D; Molinero G; Masson G; Huerín M; Nogueira JP
Lipids Health Dis; 2020 May; 19(1):111. PubMed ID: 32460779
[TBL] [Abstract][Full Text] [Related]
45. Three Musketeers for Lowering Cholesterol: Statins, Ezetimibe and Evolocumab.
Xu Q; Deng Y; Xiao J; Liu X; Zhou M; Ren Z; Peng J; Tang Y; Jiang Z; Tang Z; Liu L
Curr Med Chem; 2021; 28(5):1025-1041. PubMed ID: 32368969
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
Okere AN; Serra C
Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
[TBL] [Abstract][Full Text] [Related]
47. Cognition After Lowering LDL-Cholesterol With Evolocumab.
Gencer B; Mach F; Guo J; Im K; Ruzza A; Wang H; Kurtz CE; Pedersen TR; Keech AC; Ott BR; Sabatine MS; Giugliano RP;
J Am Coll Cardiol; 2020 May; 75(18):2283-2293. PubMed ID: 32381158
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.
Sabatine MS; Wiviott SD; Im K; Murphy SA; Giugliano RP
JAMA Cardiol; 2018 Sep; 3(9):823-828. PubMed ID: 30073316
[TBL] [Abstract][Full Text] [Related]
49. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
50. Dyslipidaemia. Assessing the efficacy and safety of evolocumab and alirocumab.
Huynh K
Nat Rev Cardiol; 2015 May; 12(5):261. PubMed ID: 25824512
[No Abstract] [Full Text] [Related]
51. PCSK9 Inhibitors and Ezetimibe Monotherapy in Patients Not Receiving Statins: A Meta-Analysis of Randomized Trials.
Benhuri B; Ueyama H; Takagi H; Briasoulis A; Kuno T
Curr Vasc Pharmacol; 2021; 19(4):390-397. PubMed ID: 32767943
[TBL] [Abstract][Full Text] [Related]
52. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
[TBL] [Abstract][Full Text] [Related]
53. First national registry on the effectiveness and safety of evolocumab in clinical practice in patients attended in cardiology in Spain. The RETOSS-CARDIO study.
Barrios V; Escobar C; Arrarte V; García E; Fernández MR; Rincón LM; Roldán C
Clin Investig Arterioscler; 2020; 32(6):231-241. PubMed ID: 32605806
[TBL] [Abstract][Full Text] [Related]
54. A review of the rationale for additional therapeutic interventions to attain lower LDL-C when statin therapy is not enough.
Shanes JG
Curr Atheroscler Rep; 2012 Feb; 14(1):33-40. PubMed ID: 22109348
[TBL] [Abstract][Full Text] [Related]
55. Strategies to overcome statin intolerance.
Agouridis AP; Nair DR; Mikhailidis DP
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):851-5. PubMed ID: 25786568
[TBL] [Abstract][Full Text] [Related]
56. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy.
Lorenzi M; Ambegaonkar B; Baxter CA; Jansen J; Zoratti MJ; Davies G
Clin Res Cardiol; 2019 May; 108(5):487-509. PubMed ID: 30302558
[TBL] [Abstract][Full Text] [Related]
57. Lipid management for the prevention of cardiovascular disease.
Schaefer JR
Curr Pharm Des; 2011; 17(9):852-60. PubMed ID: 21418030
[TBL] [Abstract][Full Text] [Related]
58. The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know.
Jia X; Al Rifai M; Birnbaum Y; Smith SC; Virani SS
Curr Atheroscler Rep; 2019 Apr; 21(6):20. PubMed ID: 30941517
[TBL] [Abstract][Full Text] [Related]
59. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
Lancellotti P; Pierard LA; Scheen AJ
Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
[TBL] [Abstract][Full Text] [Related]
60. [Inhibitors of PCSK9].
Petrova-Slater I; Denegri A; Pasotti E; Rossi MG; Spirk D; Riesen WF; Moccetti T; Moccetti M
Rev Med Suisse; 2017 Apr; 13(558):821-825. PubMed ID: 28727332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
